Approved by CQI on January 14, 2019
STRENGTHS
|
WEAKNESSES
|
OPPORTUNITIES
|
THREATS
|
The
topic of Quality is timely, relevant, and international in scope.
|
The
scope of quality is sufficiently broad that CQI has dependencies on
activities of multiple other WGs. Within HL7 there is improved understanding
of the domain and scope of the workgroup but there are still some gaps.
|
Movement
to FHIR aligns measurement and clinical decision support activities around a
more standard clinical model. It also provides opportunity to communicate
needs to each resource owner WG to align direct care and secondary use
concerns.
|
Standards
for quality continue to evolve and are likely to continue to change.
Speed
required for standard development to support US programs.
|
- ·
Outstanding mix of expertise and perspective: measure developers
[physician, hospital, health plan], vendors, clinical terminologists, and
quality data receivers, regulators and clinical decision support stakeholders.- ·
The Clinical Quality Framework collaborative initiative with CQI and
CDS to encourage new opportunities for implementers (both vendors and
provider organization staff) to pilot and to comment on CQI-related
standards.
|
Limited
stakeholder (clinicians, consumers) representation and participation; limited
users’ experiences.
|
- ·
Encourage greater direct stakeholder participation in CQI WG,
including payers and clinicians and Connectathon testing of standards. - ·
Reach out internationally for increased input.
|
Large
volume of work to be completed
Work is
driven by US programs; but the workgroup needs to include the international
perspective.
|
Member
involvement in their national projects.
|
Limited
availability of resources and availability to do work.
|
Expand
international participation and engagement.
|
Quickly
changing landscape and regulatory requirements.
|
